Drug quality has always been an inevitable priority for players in the pharmaceutical industry. On an average, the Food and Drug Administration (FDA) approves 28 new drugs annually for production into the market. Apart from the promise of a drug on a medical basis, the documentation that follows through the entire clinical trial lifecycle has to comply with rigorous pharma regulatory measures and other cross-industry mandates such as USDA and FCPA.